Abstract
Objectives: Both use of “smart” inhalers as well as suppression of FeNO can provide objective evidence of non-adherence. We report the effect of this combination on clinical outcomes in severe asthma.
Methods: Consecutive consenting patients with FeNO levels ≥ 45 ppb on 2 occasions and meeting criteria for biologics were included. Baseline high-dose ICS/LABA/LAMA combination/s inhalers were switched to mometasone/indacaterol/glycopyrronium (Enerzair® Breezhaler®). This inhaler comes with a sensor that connects via Bluetooth to an app, which records every time the inhaler is used. Inhaler technique and the use of the app were taught, FeNO checked recorded at baseline. At 4 weeks adherence data and asthma control was reviewed; FeNO levels checked; a decision made whether to proceed to biologics; and follow up arranged. Those identified as non-adherent (< 85% inhaler use and / or ≥42% FeNO suppression) were educated on compliance.
Results: In the 24 patients (median age 52 [19-81], 15 female) included, median FeNO level decreased from 81 to 45.5 ppb (p<0.01). 14 patients did not proceed to biologics (Table 1).
Conclusion: Utilisation of smart inhalers together with FeNO suppression is feasible objective measure. FeNO suppression in conjunction with good adherence and improved asthma control suggests that objective monitoring may lead to better asthma control.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 3865.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
